Galapagos' CAR-T therapy GLPG5101 shows promise but faces challenges with limited data, cash reserves, and competition in the ...

These long-term data support axicabtagene ciloleucel as a highly effective therapeutic approach for patients with relapsed or ...

Gilead Sciences presents five-year Phase II ZUMA-5 trial results for Yescarta in relapsed non-Hodgkin lymphomas, showing a 90 ...

The Zacks Daily presents the best research output of our analyst team. Today's Daily features new research reports on 16 ...